Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience
Open Access
- 23 February 2016
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 5 (2)
Abstract
Background: The subcutaneous implantable cardioverter defibrillator (S‐ ICD ) has been developed to avert risks associated with transvenous defibrillator leads. The technology is attractive for younger patients, such as those with hypertrophic cardiomyopathy (HCM). However, there are limited data on S‐ ICD use in HCM . Methods and Results: HCM patients identified at risk for sudden death were considered for S‐ ICD implantation. Patients were screened for potential oversensing by surface electrocardiography (ECG). At implant, defibrillation threshold ( DFT ) testing was performed at 65, 50, and 35 joules (J). Twenty‐seven patients were considered for S‐ ICD implantation, and after screening, 23 (85%) remained eligible. The presence of a bundle branch block was associated with screening failure, whereas elevated body mass index (BMI) showed a trend toward association. One patient passed screening at rest, but failed with an ECG obtained after exercise. At implant, the S‐ ICD terminated ventricular fibrillation ( VF ) with a 65J shock in all 15 implanted patients and a 50J shock was successful in 12 of 15. A 35J shock terminated VF in 10 of 12 patients. DFT failure at 50 J was associated with a higher BMI . There were no appropriate shocks after a median follow‐up of 17.5 (3–35) months, and 1 patient received an inappropriate shock attributable to a temporary reduction in QRS amplitude while bending forward, resulting in oversensing, despite successful screening. Conclusions: In a high‐risk HCM cohort without a pacing indication referred for consideration of an ICD , the majority were eligible for S‐ ICD . The S‐ ICD is effective at recognizing and terminating VF at implant with a wide safety margin.Keywords
This publication has 15 references indexed in Scilit:
- Safety and Efficacy of a Totally Subcutaneous Implantable-Cardioverter DefibrillatorCirculation, 2013
- Prevention of Sudden Cardiac Death With Implantable Cardioverter-Defibrillators in Children and Adolescents With Hypertrophic CardiomyopathyJACC, 2013
- A Primer on Arrhythmias in Patients with Hypertrophic CardiomyopathyCurrent Cardiology Reports, 2012
- Clinical Predictors of Fidelis Lead FailureCirculation, 2012
- 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic CardiomyopathyJACC, 2011
- Longevity of Sprint Fidelis Implantable Cardioverter-Defibrillator Leads and Risk Factors for FailureCirculation, 2011
- Defibrillation Threshold Testing in Patients with Hypertrophic CardiomyopathyPacing and Clinical Electrophysiology, 2010
- Risk Factors for Implantable Defibrillator Lead Fracture in a Recalled and a Nonrecalled LeadJournal of Cardiovascular Electrophysiology, 2010
- factors predicting success rate and recurrence of atrial fibrillation after first electrical cardioversion in patients with persistent atrial fibrillationClinical Cardiology, 2001
- Efficacy of Implantable Cardioverter–Defibrillators for the Prevention of Sudden Death in Patients with Hypertrophic CardiomyopathyNew England Journal of Medicine, 2000